A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy

Trial Profile

A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2016 Status changed from active, no longer recruiting to discontinued.
    • 12 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.
    • 12 Aug 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top